Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 20/20 | 0.59 |
| ▸ | EGFR | P00533 | 2/20 | 0.51 |
| ▸ | ABL1 | P00519 | 1/20 | 0.46 |
| ▸ | ABL2 | P42684 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27194876 | 1.00 | SRC (0.59) | SRCEGFRABL1ABL2 | |
| SCHEMBL25417491 | 1.00 | SRC (0.59) | SRCEGFRABL1ABL2 | |
| SCHEMBL30035929 | 0.87 | SRC (0.58) | SRCEGFRABL1ABL2 | |
| SCHEMBL31463180 | 0.87 | SRC (0.58) | SRCEGFRABL1ABL2 | |
| SCHEMBL19180435 | 0.81 | SRC (0.49) | SRCEGFRABL1 | |
| SCHEMBL28627629 | 0.80 | SRC (0.66) | SRCEGFRABL1ABL2 | |
| SCHEMBL29926654 | 0.80 | SRC (0.66) | SRCEGFRABL1ABL2 | |
| SCHEMBL28627632 | 0.80 | SRC (0.66) | SRCEGFRABL1ABL2 | |
| SCHEMBL25390196 | 0.76 | SRC (0.46) | SRCEGFR | |
| SCHEMBL26791254 | 0.75 | SRC (0.64) | SRCEGFRABL1ABL2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116249534-B | Crystallization of pyrimidine compounds | 大鹏药品工业株式会社 | 2025-03-25 | — | — | CN | disclosed |
| CN-113271950-B | Pyrimidine compound or salt thereof | 大鹏药品工业株式会社 | 2024-04-30 | — | — | CN | disclosed |
| EP-4351737-A2 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | Taiho Pharmaceutical Co., Ltd. (JP) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022251095-A2 | TREATMENT METHODS FOR SUBJECTS WITH CANCER HAVING AN ABERRATION IN EGFR AND/OR HER2 | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2022-12-01 | — | — | WO | disclosed |